RecruitingPhase 3NCT05899179
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Studying Tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Principal Investigator
- Shuihua Lu, bachelorShenzhen Third People's Hospital
- Intervention
- Recombinant Mycobacterium Tuberculosis Fusion Protein(biological)
- Enrollment
- 780 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2023 – 2025
Study locations (8)
- The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
- Anhui Chest Hospital, Hefei, Anhui, China
- Guangzhou Municipal Hospital of Chest Medicine, Guangzhou, Guangdong, China
- The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China
- LiuZhou People's Hospital, Liuchow, Guangxi, China
- Changsha Central Hospital, Changsha, Hunan, China
- Wuxi NO.5 People's Hospital, Wuxi, Jiangsu, China
- Wuhan Institute for Tuberculosis Control, Wuhan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05899179 on ClinicalTrials.govOther trials for Tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07164742Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)Johns Hopkins University
- RECRUITINGNCT0707721318F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis PatientsChildren's Hospital Medical Center, Cincinnati
- ENROLLING BY INVITATIONNANCT06984887Evaluation of New TB Diagnostic Tests (NATs) in PakistanMercy Corps Pakistan
- RECRUITINGNCT07018076Candidate Clinical Correlate of Prognostic Outcome for TB StudyUniversity of California, San Francisco
- RECRUITINGNANCT07271225Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and VomitingIndonesia University
- RECRUITINGNCT06585358DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary TuberculosisKarolinska Institutet
- RECRUITINGPHASE3NCT06497465Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentJohns Hopkins University
- RECRUITINGNCT07178860Respiratory Health and Wellbeing Post Pulmonary TuberculosisLiverpool School of Tropical Medicine